The +869T/C polymorphism in the transforming growth factor- beta 1 gene is associated with the severity and intractability of autoimmune thyroid disease

The severity of Hashimoto's disease (HD) and the intractability of Graves' disease (GD) vary among patients. To clarify whether the +869T/C polymorphism in the transforming growth factor- beta 1 (TGF- beta 1) gene, which is associated with TGF- beta 1 expression, is involved in the intract...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical and experimental immunology 2008-03, Vol.151 (3), p.379-382
Hauptverfasser: Yamada, H, Watanabe, M, Nanba, T, Akamizu, T, Iwatani, Y
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The severity of Hashimoto's disease (HD) and the intractability of Graves' disease (GD) vary among patients. To clarify whether the +869T/C polymorphism in the transforming growth factor- beta 1 (TGF- beta 1) gene, which is associated with TGF- beta 1 expression, is involved in the intractability of GD and severity of HD, we genotyped the TGF- beta 1+869T/C polymorphism by polymerase chain reaction-restriction fragment length polymorphism method in genomic DNA samples from 33 patients with HD who developed hypothyroidism before they were 50years old (severe HD) and 30 untreated, euthyroid patients with HD who were older than 50years (mild HD). We also examined 48 euthyroid patients with GD who had been under treatment and were still positive for anti-thyrotropin receptor antibodies (intractable GD), 20 euthyroid patients with GD in remission and 45 healthy controls. The frequency of the T allele and the TT genotype were higher in patients with severe HD than in those with in mild HD. In contrast, the frequency of the CC genotype was higher in patients with intractable GD than in patients with GD in remission. In conclusion, the +869T/C polymorphism in the TGF- beta 1 gene is associated with the severity and intractability of autoimmune thyroid disease.
ISSN:0009-9104
1365-2249
DOI:10.1111/j.1365-2249.2007.03575.x